1. Development and characterization of an indirect ELISA to detect SARS-CoV-2 spike protein-specific antibodies
- Author
-
Christine Dahlke, Cornelius Rohde, Alexandra Kupke, Sandro Halwe, Stephan Becker, Susanne Berghöfer, Christian Keller, Astrid Herwig, Helena Müller, Petra Neubauer-Rädel, Dirk Becker, Florian Klein, Markus Eickmann, Lutz Gieselmann, Meryem S. Ercanoglu, and Verena Krähling
- Subjects
0301 basic medicine ,Clinical diagnostic ,Coronavirus disease 2019 (COVID-19) ,viruses ,Coefficient of variation ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Immunology ,Enzyme-Linked Immunosorbent Assay ,Spike protein ,medicine.disease_cause ,Sensitivity and Specificity ,Article ,COVID-19 Serological Testing ,03 medical and health sciences ,0302 clinical medicine ,Chlorocebus aethiops ,Animals ,Humans ,Medicine ,Immunology and Allergy ,Seroconversion ,Vero Cells ,Enzyme Assays ,Coronavirus ,biology ,SARS-CoV-2 ,business.industry ,COVID-19 ,Reproducibility of Results ,virus diseases ,Spike Protein ,Epithelial Cells ,Antibodies, Neutralizing ,Virology ,3. Good health ,Standard curve ,030104 developmental biology ,Spike Glycoprotein, Coronavirus ,biology.protein ,ELISA ,Antibody ,business ,030215 immunology - Abstract
The current Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) pandemic is a public health emergency of international concern. Sensitive and precise diagnostic tools are urgently needed. In this study, we developed a SARS-CoV-2 spike (S1) protein enzyme-linked immunosorbent assay (ELISA) to detect SARS-CoV-2-specific antibodies. The SARS-CoV-2 S1 ELISA was found to be specific [97.8% (95% CI, 96.7% - 98.5%)], reproducible and precise (intra-assay coefficient of variability (CV) 5.3%, inter-assay CV 7.9%). A standard curve and the interpolation of arbitrary ELISA units per milliliter served to reduce the variability between different tests and operators. Cross-reactivity to other human coronaviruses was addressed by using sera positive for MERS-CoV- and hCoV HKU1-specific antibodies. Monitoring antibody development in various samples of twenty-three and single samples of twenty-nine coronavirus disease 2019 (COVID−19) patients revealed seroconversion and neutralizing antibodies against authentic SARS-CoV-2 in all cases. The comparison of the SARS-CoV-2 (S1) ELISA with a commercially available assay showed a better sensitivity for the in-house ELISA. The results demonstrate a high reproducibility, specificity and sensitivity of the newly developed ELISA, which is suitable for the detection of SARS-CoV-2 S1 protein-specific antibody responses., Highlights • A highly sensitive and specific SARS-CoV-2 S1 ELISA was developed. • A standard curve is included to reduce variability between assays and operators. • Excellent intra-assay coefficient of variability (CV) 5.3%, inter-assay CV 7.9%. • Good correlation to the virus neutralization test VNT100.
- Published
- 2021
- Full Text
- View/download PDF